ZAI LAB LIMITED Equity Securities, FV-NI, Gain (Loss)
ZAI LAB LIMITED (ZLAB) reported Equity Securities, FV-NI, Gain (Loss) of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-08-06
- ZAI LAB LIMITED equity securities, fv-ni, gain (loss) for the quarter ending 2026-06-30 was $0.00.
- ZAI LAB LIMITED equity securities, fv-ni, gain (loss) for the quarter ending 2026-03-31 was $0.00.
- ZAI LAB LIMITED equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was $0.00.
- ZAI LAB LIMITED equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $0.00.
- ZAI LAB LIMITED equity securities, fv-ni, gain (loss) for fiscal 2025 was -$1.91M.
- ZAI LAB LIMITED equity securities, fv-ni, gain (loss) for fiscal 2024 was -$6.11M, a 318.90% decline from fiscal 2023.
- ZAI LAB LIMITED equity securities, fv-ni, gain (loss) for fiscal 2023 was $2.79M.
- ZAI LAB LIMITED equity securities, fv-ni, gain (loss) for fiscal 2022 was -$8.95M.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | -$1.91M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | -$1.91M 10-Q · filed 2025-11-06 | -$1.95M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | -$1.91M 10-Q · filed 2026-08-06 | -$1.95M derived: sum of 3 quarters · filed 2026-05-07 | -$2.87M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | -$1.91M 10-Q · filed 2026-05-07 | -$1.95M derived: sum of 2 quarters · filed 2026-05-07 | -$2.87M derived: sum of 3 quarters · filed 2026-05-07 | -$12.90M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$958.00K derived: sum of 2 quarters · filed 2026-02-26 | -$10.99M derived: sum of 3 quarters · filed 2026-02-26 | -$6.11M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$920.00K 10-Q · filed 2025-11-06 | -$10.96M derived: sum of 2 quarters · filed 2025-11-06 | -$6.07M 10-Q · filed 2025-11-06 | -$1.31M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$10.04M 10-Q · filed 2025-08-07 | -$5.15M 10-Q · filed 2025-08-07 | -$392.00K derived: sum of 3 quarters · filed 2026-02-26 | -$1.05M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $4.89M 10-Q · filed 2025-05-08 | $9.64M derived: sum of 2 quarters · filed 2026-02-26 | $8.98M derived: sum of 3 quarters · filed 2026-02-26 | $7.24M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.09M derived: sum of 2 quarters · filed 2026-02-26 | $2.35M derived: sum of 3 quarters · filed 2026-02-26 | $2.79M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$661.00K 10-Q · filed 2024-11-12 | -$2.40M derived: sum of 2 quarters · filed 2024-11-12 | -$1.97M 10-Q · filed 2024-11-12 | $1.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$1.74M 10-Q · filed 2024-08-06 | -$1.30M 10-Q · filed 2024-08-06 | $1.81M derived: sum of 3 quarters · filed 2025-02-27 | $2.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $441.00K 10-Q · filed 2024-05-08 | $3.56M derived: sum of 2 quarters · filed 2025-02-27 | $4.04M derived: sum of 3 quarters · filed 2025-02-27 | -$1.57M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.60M derived: sum of 2 quarters · filed 2025-02-27 | -$2.01M derived: sum of 3 quarters · filed 2025-02-27 | -$8.95M 10-K · filed 2025-02-27 |
| 2022-09-30 | $489.00K 10-Q · filed 2023-11-07 | -$5.13M derived: sum of 2 quarters · filed 2023-11-07 | -$12.07M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$5.62M 10-Q · filed 2023-08-07 | -$12.56M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$6.94M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$14.62M 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |